To describe the tolerance in terms of occurrence of serious adverse reactions and severe adverse reactions (injection site and systemic) within eight days after one dose of IMOVAX Polio™ administered in children and infants.

Inclusion Criteria:

• Group 1: Aged 18 months (18-20 months) on the day of inclusion
• Group 2: Aged 2 months (56-70 days) on the day of inclusion

Exclusion Criteria:

• Participation in another clinical trial in the 4 weeks preceding the trial vaccination
• Planned participation in another clinical trial during the present trial period
• Congenital or acquired immunodeficiency, immunosuppressive therapy such as long-term systemic corticosteroids therapy
• Systemic hypersensitivity to any of the vaccine components or history of a life-threatening reaction to the trial vaccine or a vaccine containing the same substances
• Chronic illness at a stage that could interfere with trial conduct or completion
• Blood or blood-derived products received in the past 3 months (for Group 1) or since birth (for Group 2)
• Any vaccination in the 4 weeks preceding the trial vaccination (except BCG and Hepatitis B [Hep B] for Group 2)
• Vaccination planned in the 4 weeks following the trial vaccination
• Group 1: Previous booster vaccination against the poliomyelitis infection with the trial vaccine or with another vaccine.
• Group 2: Previous vaccination against the poliomyelitis infection with the trial vaccine or with another vaccine.
• History of poliomyelitis infection (confirmed either clinically, serologically or microbiologically)
• Clinical or serological evidence of systemic illness including Hepatitis B, C and HIV
• Thrombocytopenia or a bleeding disorder contraindicating intramuscular vaccination
• History of/current seizures
• Febrile illness (axillary temperature ≥ 37.4°C) or acute illness on the day of inclusion